Lenograstim (Lenograstim)
Overview of Lenograstim
Lenograstim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF) that stimulates the production of neutrophils and may reduce the duration of chemotherapy-induced neutropeniaand there by reduce the incidence of associated sepsis; there is yet no evidence thet it improvesoverall survival. I
Indication of Lenograstim
Lenograstim is primarily indicated in conditions like Bone marrow transplantation, Cytotoxic-induced neutropenia, Mobilisation of peripheral blood progenitor cells, Neutropenia, Reduction in the duration of neutropenia following bone marrow transplantation.
Contraindication of Lenograstim
Lenograstim is contraindicated in conditions like Kostmans syndrome.
Side Effects of Lenograstim
The severe or irreversible adverse effects of Lenograstim, which give rise to further complications include Anemia, Anemia, Thrombocytopenia, Disturbed hepatic function, Disturbed hepatic function, Anemia, Anemia.,The symptomatic adverse reactions produced by Lenograstim are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Diarrhea, Hypotension, Bone pain, Vasculitis, Uricemia, Proteinuria, Musculoskeletal pain, Epistaxis.
Precautions of Lenograstim
Caution should be taken if tumours with myeloid characteristics (risk of the tumour growth), pre-malignant myeloid conditions is present. Reduced myeloid precursors, monitor leucocyte count (discontinue treatment if leucocylossis); monitor platelet count and hemoglobin; regular morphological and cytogenetic bone marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukemia) monitor spleen size, osteoporotic bone disease ( monitor bone marrow densityif given for more than 6 months).